Achillion Pharmaceuticals Revenue Growth: -62.35%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACHN Revenue Growth Rankings
| Overall | 1st percentile | 4364 of 4424 |
| Sector | 4th percentile | 444 of 464 in Healthcare |
| Industry | 10th percentile | 114 of 127 in Biotechnology |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ACHN related companies
ACHN News
@collegefb81 $idix,$vvus,$achn we have some of the same stocks... Im holding for the conferences, if your scared high beta stocks will kill
about 2 days ago by GArgondizza
about 2 days ago by GArgondizza
RT @collegefb81 @GArgondizza im ah trying, we need some big news, majority of my $$ is in all these biotechs $DNDN $VVUS $ACHN $IDIX > $IBB
about 2 days ago by CashN1n9
about 2 days ago by CashN1n9
@GArgondizza im ah trying, we need some big news, majority of my $$ is in all these biotechs $DNDN $VVUS $ACHN $IDIX
about 2 days ago by collegefb81
about 2 days ago by collegefb81
added to $achn and $idix gotta hold them for the weekend just in case and gains coming wit the conferences next week anyway
about 2 days ago by mthester
about 2 days ago by mthester
RT @littleguy $IDIX $ACHN $DNDN ... next week big conference, follow #BIOCEO2012, truck pulling back this week, action coming IMHO >> Smart.
about 2 days ago by onpaper
about 2 days ago by onpaper
$IDIX $ACHN $DNDN ... next week big conference, follow #BIOCEO2012, truck pulling back this week, action coming IMHO
about 2 days ago by littleguy
about 2 days ago by littleguy
$DNDN $IDIX $ACHN holding over the weekend I mean the conference is next week what a little more red right
about 2 days ago by odyssea
about 2 days ago by odyssea
$ACHN $IDIX, why the sell off? if any offers are made it usually happens over the weekend
about 2 days ago by 732allst
about 2 days ago by 732allst
crap, $ACHN selling off, maybe being put into some of our other favs....$VVUS $DNDN $IDIX ???
about 2 days ago by collegefb81
about 2 days ago by collegefb81
This week has wiped /all/ my 2012 gains, efff $IDIX, $ACHN . Out of the #BIOTECH game
about 2 days ago by fukuyama09
about 2 days ago by fukuyama09
is it this weekend that $ACHN gets the b/o offer? I cant remember what they said.
about 2 days ago by MovingRanger
about 2 days ago by MovingRanger
$ACHN made a run, now its turn for $ACHN's brother $VVUS and $IDIX to run
about 2 days ago by collegefb81
about 2 days ago by collegefb81
@collegefb81 I am holding 500 $IDIX & 500 $ACHN in my IRA come what may. Hep C deal gonna come sooner or later.
about 2 days ago by Rodg3r
about 2 days ago by Rodg3r
Morning Movers 02/07: (SATC) (BMTI) (CSTR) (MNI) Higher; (ASTX) (ACHN) (BVSN) Lower
Feb 07, 11:00AM Street Insider
Feb 07, 11:00AM Street Insider
UPDATE: Bank of America Downgrades Achillion Pharmaceuticals to Underperform
Feb 07, 7:16AM Benzinga
Feb 07, 7:16AM Benzinga
BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) Two-Notches to Underperform
Feb 07, 6:55AM Street Insider
Feb 07, 6:55AM Street Insider
Unusual 11 Midday Movers 01/20: (INSM) (SCHS) (CPY) Higher; (NCIT) (CCOI) (THS) Lower
Jan 20, 1:43PM Street Insider
Jan 20, 1:43PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACHN | 9.89 | 0.42 | 4.49% | 689.88M |
| VECO | 28.36 | 0.08 | 0.28% | 1.10B |
| AA | 10.29 | -0.35 | -3.29% | 10.95B |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
| URRE | 0.95 | -0.08 | -7.73% | 88.89M |
| ETFC | 9.21 | 0.02 | 0.22% | 2.63B |
| JRCC | 6.38 | -0.51 | -7.40% | 227.13M |
| F | 12.44 | -0.25 | -1.97% | 47.27B |
| CYTK | 1.18 | -0.01 | -0.84% | 85.29M |